

IMMUNOGEN INC  
Form 8-K  
November 13, 2006

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): November 10, 2006

**ImmunoGen, Inc.**

(Exact name of registrant as specified in its charter)

**Massachusetts**  
(State or other  
jurisdiction of  
incorporation)

**0-17999**  
(Commission File  
Number)

**04-2726691**  
(IRS Employer  
Identification No.)

**128 Sidney Street, Cambridge, MA 02139**  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (617) 995-2500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**ITEM 8.01 - OTHER EVENTS**

On November 10, 2006, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce the presentation of clinical data from a Phase I study evaluating the Company's huN901-DM1 anticancer agent for the treatment of small-cell lung cancer (SCLC) and other CD56-expressing solid tumors. HuN901-DM1 is the only anticancer agent administered in the study and the compound has been found to be well-tolerated. Additionally, huN901-DM1 showed evidence of anticancer activity, including one complete remission in a patient with recurrent Merkel cell cancer and marked tumor shrinkage in a patient with relapsed SCLC. A primary objective of the study is to determine the maximum tolerated dose (MTD) of huN901-DM1 when administered for three days in a row every 21 days. The MTD is not yet defined and enrollment continues.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS**

Exhibit No.	Exhibit
99.1	Press Release of ImmunoGen, Inc. dated November 10, 2006

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ImmunoGen, Inc.**  
(Registrant)

Date: November 13, 2006

/s/ Daniel M. Junius

Daniel M. Junius  
Executive Vice President and Chief Financial Officer

**EXHIBIT INDEX**

Exhibit No.	Exhibit
99.1	Press Release of ImmunoGen, Inc. dated November 10, 2006